Management of allergic conjunctivitis: An evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 329-336

  Epstein, Arthur B ^a   Van Hoven, Peter T ^b   Kaufman, Alan ^c   Carr, Warner W ^d  

^a North Shore Contact Lens & Vision Consultants PC   (United States)

^b Primary Eyecare Group PC   (United States)

^c OUR LADY OF MERCY MEDICAL CENTER   (United States)

^d Southern California Research   (United States)

Author keywords

Allergic conjunctivitis; Azelastine; Ocular allergy; Olopatadine; Patient perceptions

Indexed keywords

AZELASTINE; EPINASTINE; KETOTIFEN; KETOTIFEN FUMARATE; OLOPATADINE; PATADAY; PLACEBO; TEARS NATURALE; TEARS NATURALE II; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SELF REPORT;

EID: 77953473799     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s5223     Document Type: Article

References (30)

1. Scoper SV, Berdy GJ, Lichtenstein SJ, et al. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Adv Ther. 2007;24(6): 1221-1232.
2. Ciprandi G, Buscaglia S, Cerqueti PM, Canonica GW. Drug treatment of allergic conjunctivitis. A review of the evidence. Drugs. 1992;43(2):154-176.
3. Katelaris CH, Bielory L. Evidence-based study design in ocular allergy trials. Curr Opin Allergy Clin Immunol. 2008;8(5):484-488.
4. Bielory L. Ocular allergy overview. Immunol Allergy Clin North Am. 2008;28(1):1-23, v.
5. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 2007;62 (Suppl 85):9-16.
6. Berger W, Abelson MB, Gomes PJ, et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann Allergy Asthma Immunol. 2005;95(4):361-371.
7. Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol. 2005;5(5):437-440.
8. Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther. 1996;12(4):401-407.
9. Galatowicz G, Ajayi Y, Stern ME, Calder VL. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Clin Exp Allergy. 2007;37(11):1648-1656.
10. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol. 2000;106(6):1019-1032.
11. Church MK, Holgate ST, Shute JK, et al. Mast cell derived mediators. In: Middleton E, Reed CE, Ellis ET, et al. editors. Allergy Principles and Practice. St. Louis, MO: Mosby;1988. p. 146-167.
12. Leonardi A. New drug treatments for ocular allergies. Expert Rev Ophthalmol. 2007;(2):397-408.
13. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther. 2000;22(7):826-33.
14. Lanier BQ, Finegold I, D'Arienzo P, Granet D, Epstein AB, Ledgerwood GL. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin. 2004;20(8):1227-1233.
15. Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther. 2001;23(8):1272-1280.
16. Brockman HL, Momsen MM, Knudtson JR, Miller ST, Graff G, Yanni JM. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm. 2003;11(4):247-268.
17. Abelson MB, Spangler DL, Epstein AB, et al. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr Eye Res. 2007;32(12):1017-1022.
18. Pataday™ [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2006.
19. Elestat® [package insert]. Irvine, CA: Allergan, Inc; 2003.
20. Patanol® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2003.
21. Optivar® [package insert]. Somerset, NJ: MedPointe Pharmaceuticals; 2003.
22. Zaditor® [package insert]. Duluth, GA: Novartis Ophthalmics; 2001.
23. Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin Drug Metab Toxicol. 2008;4(4):453-461.
24. Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr Med Res Opin. 2007;23(6):1445-1452.
25. Chipps BE, Gower R, Kaufman A, et al. A multi-center study evaluating patient perceptions of olopatadine 0.2% in patients with allergic conjunctivitis [abstract]. 2008 Western Society of Asthma, Allergy, and Immunology annual meeting.
26. Carr WW. Comparison of drop comfort of four marketed ocular anti-allergic medications [abstract]. 2007 Eastern Allergy Conference annual meeting.
27. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol. 1993;38 (Suppl):115-132.
28. Abelson MB, Welch DL. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl. 2000;(230):60-63.
29. Scoper SV, Berdy GJ, Lichtenstein SJ, et al. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Adv Ther. 2007;24(6): 1221-1232.
30. D'Arienzo PA, Granet DB. Variability of drop comfort and its importance as a criterion in the selection of topical therapy for ocular allergy [abstract]. 2001 American Academy of Allergy, Asthma, and Immunology annual meeting, abstract #2002047.